Merrick GS, Galbreath R, Fiano R, et al. - This study was undertaken to investigate the impact of body mass index (BMI) on overall survival, freedom from distant metastases, rates of therapeutic intervention (TI), and quality of life (QOL) in active surveillance (AS) prostate cancer patients. Researchers enrolled a total of 340 consecutive, prospectively evaluated AS patients who had undergone a staging transperineal template-guided mapping biopsy before AS enrollment and were stratified by BMI. Among 340 patients, 323 (95%) were Gleason 3+3 and 17 patients (5.0%) were Gleason 3+4. The results showed that BMI did not statistically predict TI, the geographic distribution of prostate cancer, or QOL parameters at 10 years.